Benzimidazole derivatives as kinase inhibitors

Current Medicinal Chemistry

Volumn 21, Issue 20, 2014, Pages 2284-2298

  Garuti, Laura ^a   Roberti, Marinella ^a   Bottegoni, Giovanni ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

ATP competitive; Benzimidazole; Biological activity; Kinase inhibition; Multi target inhibitor; SAR; Selectivity

Indexed keywords

ADENOSINE TRIPHOSPHATE; AURORA KINASE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; CASEIN KINASE 1GAMMA INHIBITOR; CASEIN KINASE 2 INHIBITOR; CHECKPOINT KINASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; LYMPHOCYTE SPECIFIC KINASE INHIBITOR; NEK 2 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE BETA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE INHIBITOR; RAF INHBIITOR; UNCLASSIFIED DRUG; BENZIMIDAZOLE; PROTEIN KINASE INHIBITOR;

ARTICLE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; IC 50; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; PROTEIN TERTIARY STRUCTURE;

BENZIMIDAZOLES; CELL LINE; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84900307958     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140217105714     Document Type: Article

References (72)

1. El Rashhedy, A. A.; Aboul-Enein, H. Y. Benzimidazole derivatives as potential anticancer agents. Mini Rev. Med. Chem., 2013, 13, 399-407.
2. Barot, K. P.; Nikolova, S.; Ivanov, I.; Ghate, M. D. Novel research strategies of benzimidazole derivatives: a review. Mini Rev. Med. Chem., 2013, 13, 1421-1447.
3. Błaszczak-Swiatkiewicz, K.; Mikiciuk-Olasik, E. New benzimidazole derivatives as topoisomerase I inhibitors - synthesis and fluorometric analysis. Acta Pol. Pharm., 2013, 70, 451-458.
4. Armand, G.; Herve, K.; Narimene, B.; Patrice, V. Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents. Eur. J. Med. Chem., 2008, 43, 1858-1864.
5. Yoon, Y.K.; Ali, M. A.; Wei, A. C.; Choon, T.S.; Khaw, K.Y.; Murugaiyah, V.; Osman, H.; Masand, V. H. Synthesis, characterization, and molecular docking analysis of novel benzimidazolederivatives as cholinesterase inhibitors. Bioorg. Chem., 2013, 49, 33-39.
6. Matijssen, C.; Silva-Santisteban, M. C.; Westwood, I. M.; Siddique, S.; Choi, V.; Sheldrake, P.; van Montfort, R. L. M.; Blagg, J. Benzimidazole inhibitors of the protein kinase CHK2: clarification on the binding mode by flexible side chain docking and proteinligand crystallography. Bioorg. Med. Chem., 2012, 20, 6630-6639.
7. Murray, J. M.; Sweeney, Z. K.; Chan, B. K.; Balazs, M.; Bradley, E.; Castanedo, G.; Chabot, C.; Chantry, D.; Flagella, M.; Goldstein, D. M.; Kondru, R.; Lesnick, J.; Li, J.; Lucas, M. C.; Nonomiya, J.; Pang, J.; Price, S.; Salphati, L.; Safina, B.; Savy, P. P. A.; Seward, E. M.; Ultsch, M.; Sutherlin, D. P. Potent and highly selective benzimidazole inhibitors of PI3-kinase Delta. J. Med. Chem., 2012, 55, 7686-7695.
8. Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P. A.; Sato, H.; Mori, I.; West, R. I.; Shibahara, M.; Toyoda, H.; Wang, L.; Nolte, R. T.; Veal, J. M.; Cheung, M. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J. Med. Chem., 2007, 50, 4453-4470.
9. Janeczko, M.; Orzeszko, A.; Kazimierczuk, Z.; Szyszka, R.; Baier, A. CK2α and CK2α' subunits differ in their sensivity to 4,5,6,7- tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur. J. Med. Chem., 2012, 47, 345-350.
10. Sessions, E. H.; Smolinski, M.; Wang, B.; Frackowiak, B:, Chowdhury, S.; Yin, Y.; Chen, Y. T.; Ruiz, C. Lin. L.; Pocas, J.; Schroter, T.; Cameron, M. D.; LoGrasso, P.; Feng, Y.; Bannister, T. D. The development of benzimidazoles as selective rho kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1939-1943.
11. Hua, Z.; Huang, X.; Bregman, H.; Chakka, N.; DiMauro, E. F. Doherty, E. M.; Goldstein, J.; Gunaydin, H:, Huang, H.; Mercede, S.; Newcomb, J.; Patel, V. F.; Turci, S. M.; Yan, J.; Wilson, C.; Martin, M. W. 2-Phenylamino-6-cyano-1H- benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 5392-5395.
12. Saitoh, M.; Kunitomo, J.; Kimura, E.; Hayase, Y.; Kobayashi, H.; Uchiyama, N.; Kawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R.; Textor, G. S.; Snell, G. P.; Itoh, F. Design, synthesis and structure- activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. Bioorg. Med. Chem., 2009, 17, 2017-2029.
13. Solanki, S.; Innocenti, P.; Mas-Droux, C.; Boxall, K.; Barillari, C.; van Montfort, R. L. M.; Aherne, G. W.; Bayliss, R.; Hoelder, S. Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (NeK2) without binding to the back pocket and reveal a non linear structure-activity relationship. J. Med. Chem., 2011, 54, 1626-1639.
14. Peterson, E. A.; Andrews, P. S.; Be, X.; Boezio, A. A.; Bush, T. L.; Cheng, A. C.; Coats, J. R.; Colletti, A. E.; Copeland, K. W.; DuPont, M.; Graceffa, R.; Grubinska, B.; Harmange, J-C.; Kim, J. L.; Mullady, E. L.; Olivieri, P.; Schenkel, L. B.; Stanton, M. K.; Teffera, Y.; Whittington, D. A.; Cai, T.; La, D. S. Discovery of triazine- benzimidazoles as selective inhibitors of mTor. Bioorg. Med. Chem. Lett., 2011, 21, 2064-2070.
15. Shin, D.; Lee, S-C.; Heo, Y-S.; Lee, W-Y.; Cho, Y-S.; Kim, Y. E.; Hyun, Y-L.; Cho, J. M.; Lee, Y. S.; Ro, S. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3β. Bioorg. Med. Chem. Lett., 2007, 17, 5686-5689.
16. Smith, A, L.; D'Angelo, N. D.; Bo, Y. Y.; Booker, S. K.; Cee, V. J.; Herberich, B.; Hong, F-T.; Jackson, C. L. M.; Lanman, B. A.; Liu, L.; Nishimura, N.; Pettus, L. H.; Reed, A. B.; Tadesse, S.; Tamayo, N. A.; Wurz, R. P.; Yang, K.; Andrews, K. L.; Whittington, D. A.; McCarter, J. D.; Miguel, T. S.; Zalameda, L.; Jiang, J.; Subramanian, R.; Mullady, E. L.; Caenepeel, S.; Freeman, D. J.; Wang, L.; Zhang, N.; Wu, T.; Hughes, P. E.; Norman, M. H. Structure- based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases. J. Med. Chem., 2012, 55, 5188-5219.
17. Bologna, M.; Vicentini, C.; Muzi, P.; pace, G.; angelucci, A. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond. Curr. Med. Chem., 2011, 18, 2827-2835.
18. Prichard, J. R.; Cosgrove, B.D.; Hemann, M. T.; Griffith, L. G.; Wands, J. R.; Lauffenburger, D. A. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol. Cancer Ther., 2009, 8, 2183-2192.
19. Determann, R.; Dreher, J.; Baumann, K.; Preu, L.; Jones, P.G.; Totzke, F.; Schächtele, C.; Kubbutat, M. H. G.; Kunick, C. 2- Anilino-4- (benzimidazol-2-yl)pyrimidines-a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines. Eur. J. Med. Chem., 2012, 53, 254-263.
20. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinković, M.; Wyatt, P. G. Fragmentbased discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J. Med. Chem., 2009, 52, 379-388.
21. Li, Y.; Tan, C. T.; Gao, C.; Zhang, C.; Luan, X.; Chen, X.; Liu, H.; Chen, Y.; Jiang, Y. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg. Med. Chem., 2011, 19, 4529-4535.
22. Götz, C.; Gratz, A.; Kucklaender U.; Jose, J. TF-a novel cellpermeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP. Biochim. Biophys Acta., 2012, 1820, 970-977.
23. Zhang, S.; Long, H.; Yang, Y. L.; Wang, Y.; Hsieh, D.; Li, W.; Au, A.; Stoppler, H. J.; Xu, Z.; Jablons, D. M.; You, L. Inhibition of CH2α down-regulates Notch1 signalling in lung cancer cells. J. Cell. Mol. Med., 2013, 20, 1-9.
24. Makawska, M.; Lukowska-Chojnacka, E.; Wińska, P., Kuś, A.; Bilińska-Chomik,A.; Bretner, M. Design and synthesis of CK2 inhibitors. Mol. Cell Biochem., 2011, 356, 91-96.
25. Schneider, C. C.; Kartarious, S.; Montenarh, M.; Orzeszko, A. Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro. Bioorg. Med. Chem., 2012, 20, 4390-4396.
26. Duncan, J. S.; Gyenis, L.; Lenehan, J.; Bretner, M.; Graves, L. M.; Haystead, T.A.; Litchfield, D. W. An unbiased evaluation of CK2 inhibitors by chemoproteomics. Mol. Cell Proteom., 2008, 7, 1077-1088.
27. Battistutta, R.; Mazzorana, M.; Sarno, S.; Kazimierczuk, Z.; Zanotti, G.; Pinna, L. A. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromobenzimidazole. Chem. Biol., 2005, 12, 1211-1219.
28. Zien, P.; Duncan, J. S.; Skierski, J.; Bretner, M.; Litchfield, D. W.; Shugar, D. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim. Biophys. Acta, 2005, 1754, 271-280.
29. Sass, G.; Klinger, N.; Sirma, H.; Hashemolhosseini, S.; Hellerbrand, C.; Neureiter, D.; Wege, H.; Ocker, M.; Tiegs, G. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. Int. J. Oncol., 2011, 39, 433-442.
30. Schneider, C.; Hessenauer, A.; Gotz, C.; Montenarh, M. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks. Oncol. Rep., 2009, 21, 1593-1597.
31. Cozza, G.; Sarno, S.; Ruzzene, M.; Girardi, C.; Orzeszko, A.; Kazimierczuk, Z.; Zagotto, G.; Bonaiuto, E.; Di Paolo, M. L.; Pinna, L. A. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. Biochim. Biophys. Acta, 2013, 1834, 1402-1409.
32. Pagano, M. A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene, M.; Di Mira, G.; Elliott, M.; Orzeszko, A.; Cozza, G.; Meggio, F.; Pinna, L. A.; The selectivity of inhibitors of protein kinase CK2: an update. Biochem. J., 2008, 415, 353-365.
33. Gianoncelli, A.; Cozza, G.; Orzeszko, A.; Meggio, F.; Kazimierczuk, Z.; Pinna, L. A. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. Bioorg. Med. Chem., 2009, 17, 7281-7289.
34. Neff, D. K.; Lee-Dutra, A.; Blevitt, J. M.; Axe, F. U.; Hack, M. D.; Buma, J. C.; Rynberg, R.; Brummark, A.; Karlsson, L.; Breitenbucher, J, G. 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg. Med. Chem. Lett., 2007, 17, 6467-6471.
35. Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Pandit, C. R.; Karlsson, L.; Breitenbucher, J. G. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2- arylbenzimidazoles. J. Med. Chem., 2005, 48, 1873-1885.
36. Lee, S-C.; Shin, D.; Cho, J. M.; Ro, S.; Suh, Y-G. Structureactivity relationship of the 7-hydroxbenzimidazole analogs as glycogen synthase kinase 3β inhibitor. Bioorg. Med. Chem. Lett., 2012, 22, 1891-1894.
37. Sutherlin, D. P.; Baker, S.; Bisconte, A.; Blaney, P. M.; Brown, A.; Chan, B. K.; Chantry, D.; Castanedo, G.; DePledge, P.; Goldsmith, P.; Goldstein, D. M.; Hancox, T.; Kaur, J.; Knowles, D.; Kondru, R.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Safina, B. S.; Salphati, L.; Staben, S.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; Ultsch, M.; Waszkowycz, B.; Wei, B. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorg. Med. Chem. Lett., 2012, 22, 4296-4302.
38. Gong, D.; Yaguchi, S.; Yamori, T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol. Pharm. Bull., 2009, 32, 297-300.
39. Kong, D.; Yamori, T. ZSTK474, a novel phosphatidylinositol 3- kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol. Sin., 2010, 31, 1189-1197.
40. Dan. S.; Okamura, M.; Mukai, Y.; Yoshimi, H.; Inoue, Y.; Hanyu, A.; Sakaue-Sawano, A.; Imamura, T.; Miyahydroxywaki, A.; Yamori, T. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G 1 arrest of the cell cycle in vivo. Eur. J. Cancer, 2012, 48, 936-943.
41. Zhao, W.; Guo, W.; Zhou, Q.; Ma, S. N.; Wang, R.; Qiu, Y.; Jin, M.; Duan, H. Q.; Kong, D. In vitro antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells. Int. J. Mol. Sci., 2013, 14, 13577-13591.
42. Dan. S.;Okamura, M.; Mukai, Y.; Yoshimi, H.; Inoue, Y.; Hanyu, A.; Sakaue-Sawano, A.; Imamura, T.; Miyawaki, A.; Yamori, T. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G 1 arrest of the cell cycle in vivo. Eur. J. Cancer, 2012, 48, 936-943.
43. Rewcastle, G. W.; Gamage, S. A.; Flanagan, J. U.; Frederick, R.; Denny, W. A.; Baguley, B. C.; Kestell, P.; Singh, R.; Kendall, J. D.; Marshall, E. S.; Lill, C. L.; Lee, W-J.; Kolekar, S.; Buchanan, C. M.; Jamieson, S. M. F.; Shepherd, P. R. Synthesis and biological evaluation of novel analogs of the Pan class I Phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4, 6-di(4- morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). J. Med. Chem., 2011, 54, 7105-7126.
44. Miller, M. S.; Pinson, J-A.; Zheng, Z.; Jenning, I. G.; Thompson, P. E. Regioselective synthesis of 5- and 6-methoxybenzimidazole- 1,3,5-triazines as inhibitors of phosphoinositide 3-kinase. Bioorg. Med. Chem. Lett., 2013, 23, 802-805.
45. Rewcastle, G. W.; Gamage, S. A.; Flanagan, J. U.; Kendall, J. D.; Denny, W. A.; Baguley, B. C.; Buchanan, C. M.; Chao, M.; Kestell, P.; Kolekar, S.; Lee, W-J.; Lill, C. L.; Malik, A.; Singh, R.; Jamieson, S. M. F.; Shepherd, P. R. Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1- [4,6-di(morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Eur. J. Med. Chem., 2013, 64, 137-147.
46. Safina, B. S.; Baker, S.; Baumgardner, M.; Blaney,P. M.; Chan,B. K.; Chen, Y-H.; Cartwright, M. W.; Castanedo, G.; Chabot, C.; Cheguillaume, A. J.; Goldsmith, P.; Goldstein, D. M.; Goyal, B.; Hancox, T.; Handa, R. K.; Iyer, P. S.; Kaur, J.; Kondru, R.; Kenny, J. R.; Krintel, S. L.; Li, J.; Lesnick, J.; Lucas, M. C.; Lewis, C.; Mukadam, S.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Padilla, F.; Palmer, W. S.; Pang, J.; Pegg, N.; Price, S.; Reif, K.; Salphati, L.; Savy, P. A.; Seward, E. M.; Shuttleworth, S:, Sohal, S.; Sweeney, Z. K.; Tay, S.; Tivitmahaisoon, P.; Waszkowycz, B.; Wei, B., Yue, Q.; Zhang, C.; Sutherlin, D. P. Discovery of novel PI3-kinase specific inhibitors for the treatment of rheumatoid arthritis: taming CY3A4 time-dependent inhibition. J. Med. Chem., 2012, 55, 5887-5900.
47. Certal, V.; Halley, F.; Virone-Oddos, A.; Delorma, C.; Karlsson, A.; Rak, A.; Thompson, F.; Filoche-Rommé, B.; El-Ahmad, Y.; Carry, J-C.; Abecassis, P-Y.; Leieune, P.; Vincent, L.; Bonnevaux, H.; Nicolas, J-P.; Bertrand, T.; Marquette, J-P.; Michot, N.; Benard, T.; Below, P.; Vade, I.; Chatreaux, F.; Lebourg, G.; Pilorge, F.; Angouillant-Boniface, O.; Louboutin, A.; Lengauer, C.; Schio, L. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J. Med. Chem., 2012, 55, 4788-4805.
48. Sabat, M.; VanRens, J. C.; Laufersweiler, M. J.; Brugel, T. A.; Maier, J.; Golebiowski, A.; De, B.; Easwaran, V.; Hsieh, L. C.; Walter, R. L.; Mekel, M. J.; Evdokimov, A.; Janusz, M. J. The development of 2-benzimidazole substituted pyridine based inhibitors of lymphocyte specific kinase (Lck). Bioorg. Med. Chem. Lett., 2006, 16, 5973-5977.
49. Zhang, G.; Ren, P.; Gray, N. S.; Sim, T.; Liu, Y.; Wang, X.; Che, J.; Tian, S-S.; Sandberg, M. L.; Spalding, T. A.; Romeo, R.; Iskandar, M.; Chow, D.; Siedel, H. M.; Karanewsky, D. S.; He, Y. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorg. Med. Chem. Lett., 2008, 18, 5613-5621.
50. Zhang, G.; Ren, P.; Gray, N. S.; Sim, T.; Wang, X.; Liu, Y.; Che, J.; Dong, W.; Tian, S-S.; Sandberg, M. L.; Spalding, T. A.; Romeo, R.; Iskandar, M.; Wang, Z.; Seidel, H. M.; Karanewsky, D. S.; He, Y. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Bioorg. Med. Chem. Lett., 2009, 19, 6691-6695.
51. Westwood, I.; Cheary, D-M.; Baxter, J. E.; Richards, M. W.; van Montfort, R. L. M.; Fry, A. M.; Bayliss, R. Insights into the conformational variability and regulation of human NeK2 kinase. J. Mol. Biol., 2009, 386, 476-485.
52. Buchstaller, H-P.; Burgdorf, L.; Finsinger, D.; Stieber, F.; Sirrenberg, C.; Amendt, C.; Grell, M.; Zenke, F.; Krier, M. Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 2264-2269.
53. Ramurthy, S.; Subramanian, S.; Aikawa, M.; Amiri, P.; Costales, A.; Dove, J.; Fong, S.; Jansen, J. M.; Levine, B.; Ma, S.; McBride, C. M.; Michaelian, J.; Pick, T.; Poon, D. J.; Girish, S.; Shafer, C. M.; Stuart, D.; Sung, L.; Renhowe, P. A. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem., 2008, 51, 7049-7052.
54. Chung, J. Y.; Cho, S. J.; Cho, A. E.; Hah, J-M. In silico binding free energy predictability with δ-δ interaction energy-augmented scoring function: Benzimidazole Raf inhibitors as a case study. Bioorg. Med. Chem. Lett., 2012, 22, 3278-3283.
55. Emmitte, K. A.; Adjebang, G. M.; Andrews, C. W.; BadiangAlberti, J. G.; Bambal, R.; Chamberlain, S. D.; Davis-Ward, R. G.; Dickinson, H. D.; Hassler, D. F.; Hornberger, K. R.; Jackson, J. R.; Kuntz, K. W.; Lansing, T. J.; Mook Jr, R. A.; Nailor, K. E.; Pobanz, M. A.; Smith, S. C.; Sung, C-M.; Cheung, M. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg. Med. Chem. Lett., 2009, 19, 1694-1697.
56. Olmos, D.; Barker, D.; Shama, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B.; Barriuso, J.; Medani, H.; Degenhardt, Y. Y.; Allred, A. J.; Smith, D. A.; Murray, S. C.; Lampkin, T. A.; Dar, M. M.; Wilson, R.; de Bono, J. S.; Blagde, S. P. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res., 2011, 17, 3420-3430.
57. Murugan, R. N.; Park, J-E.; Kim, E-H.; Shin, S. Y.; Cheong, C.; Lee, K. S.; Bang, J.K. PLK1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol. Cells, 2011, 32, 209-220.
58. Murthy, D.; Attri, K. S.; Gokhale, R. S. Network, nodes and nexus: systems approach to multitarget therapeutics. Curr. Opin. Biochnol., 2013, 24, 1-8.
59. Soffietti, R.; Trevisan, E.; Rudà, R. Targeted therapy in brain metastasis. Curr. Opin. Oncol., 2012, 24, 679-686.
60. Bologna, M.; Vicentini, C.; Muzi, P.; Pace, G.; Angelucci, A. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond. Curr. Med. Chem., 2011, 18, 2827-2835.
61. Petrelli, A.; Valabrega, G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin. Pharmacother., 2009, 10, 589-600.
62. Laird. A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs, 2003, 12, 51-64.
63. Santo, L.; Hideshima, T.; Cirstea, D.; Bandi, M.; Nelson, E. A.; Gorgun, G.; Rodig, S.; Vallet, S.; Pozzi, S.; Patel, K.; Unitt, C.; Squires, M., Hu, Y.; Chauhan, D.; Mahindra, A.; Munshi, N. C.; Anderson, K. C.; Raje, N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin. Cancer Res., 2011, 17, 3259-3271.
64. Tanaka, R.; Squires, M. S.; Kimura, S.; Yokota, A.; Nagao, R.; Yamauchi, T.; Takeuchi, M.; Yao, H.; Reule, M.; Smith, T.; Lyons, J. F.; Thompson, N. T.; Ashihara, E.; Ottmann, O. G.; Maekawa, T. Activity of the multitargeted kinase inhibitor, AT9283, in imatinibresistant BCR-ABL-positive leukemic cells. Blood, 2010, 116, 2089-2095.
65. Qi, W.; Liu, X.; Cooke, L. S.; Persky, D. O.; Miller, T. P.; Squires, M.; Mahadevan, D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int. J. Cancer, 2012, 130, 2997-3005.
66. Jayanthan, A.; Cooper, T. M.; Hoeksema, K. A.; Lotfi, S.; Woldum, E.; Lewis, V. A.; Narendran, A. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pedriatic acute leukemia cells. Leuk. Lymphoma, 2013, 54, 1505-1516.
67. Shah, M.; Gallipoli, P.; Lyons, J.; Holyoake, T.; Jorgensen, H. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells Mol. Dis., 2012, 48, 199-201.
68. Dawson, M. A.; Curry, J. E.; Barber, K.; Beer, P. A.; Graham,. B.; Lyons, J. F.; Richardson, C. J.; Scott, M. A.; Smyth, T.; Squires, M. S.; Thompson, N. T.; Green, A. R.; Wallis, N. G. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferatve disorders. Br. J. Haematol., 2010, 150, 46-57.
69. Kimura, S. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. Curr. Opin. Investig. Drugs, 2010, 11, 1442-1449.
70. Zheng, Y.; Zheng, M.; Ling, X.; Liu, Y.; Xue, Y.; An, L.; Gu, N.; Jin, M. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 3523-3530.
71. Yewale, C.; Baradia, D.; Vhora, I.; Patil, S.; Misra, A. Epirdemal growth factor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.
72. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer, 2010, 10, 130-137.